Insider Trading June 4, 2026 05:46 PM

Star Equity CEO Jeffrey Eberwein Expands Ownership with $74,290 Share Acquisition

Executive purchases occur near 52-week high as company navigates preferred stock issuance and revised compensation frameworks

By Jordan Park STRR

Jeffrey E. Eberwein, Chief Executive Officer and Director of Star Equity Holdings, Inc. (NASDAQ:STRR), executed a series of open-market purchases totaling $74,290 between June 2 and June 4, 2026. The transactions, conducted at prices between $11.41 and $11.61 per share, increased his direct equity stake to 1,087,538 shares. This activity occurs as the stock trades near its 52-week high of $11.99, reflecting a period of strong performance with a 31% return over the past year. Concurrently, the company has activated an At Market Issuance Sales Agreement for up to $8.7 million in preferred stock and updated executive compensation structures for 2025 and 2026.

Star Equity CEO Jeffrey Eberwein Expands Ownership with $74,290 Share Acquisition
STRR

Key Points

  • CEO Jeffrey Eberwein accumulated $74,290 in common stock between June 2 and June 4, 2026, increasing his direct ownership to 1,087,538 shares.
  • The stock trades near its 52-week high of $11.99, reflecting a 31% annual return and aggressive share buybacks by management.
  • The company activated an At Market Issuance Sales Agreement for up to $8.7 million in preferred stock and revised executive compensation structures for 2025 and 2026.

Jeffrey E. Eberwein, who serves as both Chief Executive Officer and a Director of Star Equity Holdings, Inc. (NASDAQ:STRR), has significantly expanded his direct equity position through a series of open-market transactions. Between June 2 and June 4, 2026, Eberwein acquired $74,290 worth of the company's common stock. These purchases were executed at varying prices, ranging from $11.41 to $11.61 per share, demonstrating a consistent accumulation of ownership during this specific window.

The timing of these acquisitions is notable given the stock's recent performance. Shares of Star Equity Holdings have been trading near their 52-week high of $11.99, with the current price recorded at $11.65. The company has delivered a robust 31% return over the past year and a 16% gain over the last six months, according to market data. Management has also been aggressively buying back shares, contributing to strong returns over both the last month and three months.

On June 2, Eberwein purchased 4,881 shares at a weighted average price of $11.61 per share. This transaction increased his direct holdings to 1,086,007 shares. This total includes 21,125 shares of restricted stock credited under the Issuer’s 2009 Incentive Plan and 6,750 restricted stock units (RSUs). Each share of restricted stock and RSU represents the right to receive one share of common stock upon settlement. The figure excludes 2,000 shares indirectly owned in contributory 401(k) and IRA accounts.

Further purchases were made on June 3, when Eberwein acquired an additional 101 shares at $11.51 per share. This transaction increased his direct holdings to 1,086,108 shares, which included 1,058,233 shares of common stock, alongside the previously mentioned restricted stock and RSUs. The final reported transaction took place on June 4, with Eberwein purchasing 1,430 shares at $11.51 per share. After this acquisition, his direct ownership totaled 1,087,538 shares, comprising 1,059,663 shares of common stock, in addition to the 21,125 restricted shares and 6,750 RSUs. As with previous reports, 2,000 shares held indirectly in 401(k) and IRA accounts were not included in these direct ownership figures.

Analysis from InvestingPro suggests the stock appears undervalued based on its Fair Value assessment, placing it among potential opportunities on the platform’s Most Undervalued list. The company carries a market cap of $42.69 million. For investors seeking comprehensive analysis, Star Equity is one of 1,400+ US equities covered by InvestingPro’s detailed Pro Research Reports, which transform complex Wall Street data into clear, actionable intelligence through intuitive visuals and expert analysis.

In other recent developments, Star Equity Holdings announced an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. This agreement allows the company to offer and sell shares of its 10% Series A Cumulative Perpetual Preferred Stock for up to $8.7 million. The company stated that it is not obligated to sell any shares under this agreement, and the sales agent will work to sell the shares based on the company’s instructions.

Additionally, Star Equity Holdings updated its executive compensation plans for 2025 and 2026. The Compensation Committee approved modifications to the 2025 executive incentive compensation program. Under the revised plan, CEO Jeffrey E. Eberwein will receive a restricted stock unit bonus valued at $268,380. Other executives, including COO Richard K. Coleman, Jr. and CAO Matthew K. Diamond, will receive cash and RSU bonuses. Jacob Zabkowicz, Global CEO of Hudson Talent Solutions LLC, will receive a cash bonus without an RSU bonus.

Risks

  • The At Market Issuance Sales Agreement allows for the sale of up to $8.7 million in preferred stock, but the company is not obligated to sell any shares, introducing uncertainty about capital raising timelines.
  • Executive compensation revisions include significant RSU and cash bonuses for top leadership, which may impact future equity dilution and cash flow requirements.
  • The stock's performance near its 52-week high suggests potential valuation sensitivity, requiring careful monitoring of market momentum and fundamental drivers.

More from Insider Trading

Rackspace Technology Executive Offloads Shares to Cover Tax Obligations Amid Stock Surge Jun 4, 2026 Fermi Inc. Executive Unloads $1M in Shares Amid Ongoing Corporate Restructuring Jun 4, 2026 Veracyte Executive Sells Nearly $700K in Shares Amid Product Rollouts and Analyst Upgrades Jun 4, 2026 Veracyte Executive Traces Share Disposition Amid Clinical Milestones and Valuation Scrutiny Jun 4, 2026 Veracyte CFO Executes $177K Stock Sale Amid Clinical Trial Updates and Analyst Revisions Jun 4, 2026